Why the study?
Does perindopril 3.5 mg/amlodipine 2.5 mg single-pill combination reduce blood pressure more effectively than RAS-inhibitor monotherapy in patients with hypertension?
Population
5496 patients with hypertension from three randomized controlled trials
Comparison
Perindopril 3.5 mg/amlodipine 2.5 mg single-pill… vs Renin-angiotensin system-inhibitor monotherapies
Design
Meta-analysis
Follow-up
1 month
Key result
Perindopril 3.5 mg/amlodipine 2.5 mg significantly lowered systolic (P=0.002) and diastolic (P=0.005) blood pressure after 1 month compared with RAS-inhibitor monotherapies in hypertension.
Authors
Loading...
Supports first-line low-dose perindopril/amlodipine SPC in hypertension; extends meta-analytic evidence favoring early combination over RAS monotherapy.
Meta-Analysis (n=5,496)
Does perindopril 3.5 mg/amlodipine 2.5 mg single-pill combination reduce blood pressure more effectively than RAS-inhibitor monotherapy in patients with hypertension?
p-value: p=0.002
A single-pill combination of perindopril 3.5 mg and amlodipine 2.5 mg provides significantly greater blood pressure reduction at 1 month compared to RAS-inhibitor monotherapy as first-line treatment for hypertension.
Laurent et al. (2018) conducted a meta-analysis in Hypertension (n=5,496). Perindopril/amlodipine vs. RAS-inhibitor monotherapies (perindopril 5 mg, irbesartan 150 mg or valsartan 80 mg) was evaluated on Reduction in systolic and diastolic blood pressure (p=0.002). Perindopril 3.5 mg/amlodipine 2.5 mg significantly lowered systolic (P=0.002) and diastolic (P=0.005) blood pressure after 1 month compared with RAS-inhibitor monotherapies in hypertension.